Genmab A/S Sponsored ADR $GMAB Shares Acquired by Cibc World Market Inc.

Cibc World Market Inc. grew its holdings in Genmab A/S Sponsored ADR (NASDAQ:GMAB) by 31.2% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 367,282 shares of the company’s stock after purchasing an additional 87,350 shares during the quarter. Cibc World Market Inc.’s holdings in Genmab A/S were worth $11,312,000 at the end of the most recent quarter.

Several other large investors have also modified their holdings of GMAB. Paradigm Biocapital Advisors LP acquired a new stake in shares of Genmab A/S in the third quarter valued at approximately $117,063,000. Orbis Allan Gray Ltd boosted its position in Genmab A/S by 38.7% during the second quarter. Orbis Allan Gray Ltd now owns 7,920,400 shares of the company’s stock worth $163,635,000 after acquiring an additional 2,209,659 shares during the last quarter. Pictet Asset Management Holding SA acquired a new stake in Genmab A/S during the fourth quarter worth approximately $33,835,000. Perpetual Ltd acquired a new stake in Genmab A/S during the fourth quarter worth approximately $25,478,000. Finally, Deep Track Capital LP acquired a new stake in Genmab A/S during the third quarter worth approximately $14,760,000. 7.07% of the stock is currently owned by institutional investors and hedge funds.

Genmab A/S Stock Performance

NASDAQ:GMAB opened at $25.15 on Friday. The company has a quick ratio of 2.17, a current ratio of 2.18 and a debt-to-equity ratio of 0.87. The company has a market cap of $15.68 billion, a P/E ratio of 19.05, a P/E/G ratio of 1.49 and a beta of 0.85. Genmab A/S Sponsored ADR has a fifty-two week low of $20.23 and a fifty-two week high of $35.43. The firm’s 50 day moving average is $26.90 and its two-hundred day moving average is $29.43.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on GMAB shares. Wolfe Research started coverage on shares of Genmab A/S in a research report on Friday, March 27th. They set an “outperform” rating and a $32.00 target price on the stock. The Goldman Sachs Group upgraded shares of Genmab A/S from a “neutral” rating to a “buy” rating in a research report on Wednesday, April 22nd. BNP Paribas Exane upgraded shares of Genmab A/S from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, April 22nd. Morgan Stanley started coverage on shares of Genmab A/S in a research report on Monday, February 16th. They set an “equal weight” rating and a $34.00 target price on the stock. Finally, Truist Financial started coverage on shares of Genmab A/S in a research report on Wednesday, May 27th. They set a “buy” rating and a $40.00 target price on the stock. One research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Genmab A/S has an average rating of “Moderate Buy” and an average price target of $37.93.

Genmab A/S Company Profile

Genmab A/S is a Denmark-based biotechnology company specializing in the discovery and development of antibody therapeutics for the treatment of cancer. Since its founding in 1999 and with headquarters in Copenhagen, Genmab has built a robust research platform focused on harnessing novel antibody engineering technologies to create next-generation therapies. The company’s work centers on identifying targets in hematologic malignancies and solid tumors, advancing its proprietary molecules from early discovery through clinical development.

Genmab’s portfolio includes products developed in collaboration with leading global pharmaceutical partners.